Key result
Colchicine shows promise as a novel CAD therapy by targeting underlying chronic inflammation.
Why the study?
Colchicine remains a contentious treatment option for coronary heart disease, despite mounting evidence supporting its role in targeting chronic inflammation.
Does colchicine improve outcomes in patients with coronary artery disease?
Does colchicine improve outcomes in patients with coronary artery disease?
Colchicine is highlighted as a potential novel, cost-effective therapy for coronary artery disease by targeting underlying chronic inflammation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for colchicine in CAD; should not yet change practice pending randomized trials.
For more than six decades, ischemic heart disease has sustained as the world’s leading cause of death. Growing evidence suggests chronic inflammation as the underlying pathophysiology of this illness. Due to this, inflammatory markers have become a mainstay of diagnosing, prognosticating, and following up the effectiveness of therapy. Colchicine remains a contentious treatment option for coronary heart disease, despite mounting evidence to the contrary from recent studies. This article discusses the basics of inflammation, the role of colchicine, various clinical studies, and the latest guidelines on colchicine. Colchicine has the potential to develop into a cheap, novel, and effective therapy for coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Kartik Jadhav (2024) conducted a review in Coronary artery disease. Colchicine was evaluated. Colchicine has the potential to develop into a cheap, novel, and effective therapy for coronary artery disease by targeting underlying chronic inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: